150

MAR	E 29	2015 RADE	AND OFFICE OF
		l	T

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/718,834		
Filing Date	November 21, 2003		
First Named Inventor	Margot O'Toole et al.		
Group Art Unit	1646		
Examiner Name	Unassigned		
Attorney Docket Number	031896-091000		

Total Number of Pages in This Submission	3 Attorney Docket Number		031896-091000		
ENCLOSURES (check all that apply)					
Fee Transmittal Form Fee Attached Amendment / Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawing     Declara     Licensin     Petition     Applica     Power of Change     Termina     Request	ENCLOSURES (check all that apply)  Assignment Papers (for an Application) Drawing(s) Declaration and Power of Attorney Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s)		After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Application Data Sheet Request for Corrected Filing Receipt with Enclosures A self-addressed prepaid postcard for acknowledging receipt Other Enclosure(s) (please identify below): PTO-1449 w/References.	
	Remarks	Remarks  The Commissioner is hereby authorized to charge any additional fees required or credit any overpayments to Deposit Account No. 19-2380 for the above identified docket number.			
SIGNA	TURE OF APPI			GENT	
Firm or Individual name Raymon Nixon I 401 9 <sup>th</sup> Suite 90 Washin	Raymond Van Dyke (Reg. No. 34,746) Nixon Peabody LLP 401 9 <sup>th</sup> Street, N.W. Suite 900 Washington, D.C. 20004-2128				
Signature	y Va	I had			
Date March 2	29, 2005	·			
I hereby certify that this corresponde	nce is being:	G OR TRANSMISSION	_	7 CFR 1.8(a)]  w with sufficient postage as first	

deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop \_\_\_\_\_\_\_, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450

transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) \_\_\_\_\_\_.

(703)	
Date	Signature
	Typed or printed name

Application No. 10/718,834 Docket No. 031896-091000

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Margot O'Toole et al.	)	Examiner: Unassigned
MAR 2 9 2005 Serial No. 10/718,834	)	Group Art Unit: 1646
Filed: November 21, 2003	)	
For: COMPOSITION AND FOR TREATING	)	
LUPUS NEPHRITIS	)	

## **INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within three (3) months of the filing of this application or entry into the national stage of this application, or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

These documents were cited during the prosecution of the corresponding International application. A copy of the International Search Report is attached setting forth the portion of each document considered relevant by the Examiner

It is requested that the accompanying PTO-1449 be considered and made of record in the above-identified application. To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initial a copy of this form be returned to the undersigned.

The Commissioner is hereby authorized to charge any fees connected with this filing which may be required now, or credit any overpayment to Deposit Account No. 19-2380.

Respectfully submitted,

Date: March 29, 2005

Raymond Van Dyke

Registration No. 34,746

NIXON PEABODY LLP Suite 900 401 9<sup>th</sup> Street, N.W. Washington, DC 20004-2128 Telephone: (202) 585-8000 MAR 2 9 2005 25146

## Complete if Known Substitute for form 1449A/PTO 10/718,834 Application Number INFORMATION DISCLOSURE November 21, 2003 Filing Date STATEMENT BY APPLICANT Margot O'Toole et al. First Named Inventor (use as many sheets as necessary) 1646 Art Unit Unassigned **Examiner Name** of 1 Sheet 1 Attorney Docket Number 031896-091000

	U.S. PATENT DOCUMENTS				
Examiner Initials	Cite No.1	U.S. Patent Document  Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			_

		FC	REIGN PATENT DO	CUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Kind Code <sup>3</sup> Country Code <sup>3</sup> Number <sup>4</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		OTHER PRIOR A	ART – NON PATENT LI	TERATURE DOCUMENTS		
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>	
······································		PCT International Search Report; PCT/US03/37317; mailed January 6, 2005, 6 pages				
		BALOW ET AL., New Prospects For Treatment of Lupus Nephritis, SEMINARS IN NEPHROLOGY, Vol. 20, No. 1, pgs. 32-39, 2000				
		DAVIS ET AL., Lupus Nephi 423, 1996	ritis, Current Opini	ON IN RHEUMATOLOGY, Vo	l. 8, No. 5, pgs. 415-	
		MERCADAL ET AL., Lupus Expert Opinion Pharmacot	•	•	ogical Treatments,	
	RAHMAN ET AL., A Novel Susceptibility Locus On Chromosone 2 in the (New Zealand Black x New Zealand White) F <sub>1</sub> Hybrid Mouse Model of Systematic Lupus Erythematosus, THE JOURNAL OF IMMUNOLOGY, Vol. 168, No. 6, pgs. 3042-3049, 2002					
		BP TSAO, Genetic Susceptible	ility to Lupus Nephri	tis, Lupus, Vol. 7, No. 9, p	ogs. 585-590, 1998	

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.